The antibiotic R&D pipeline: An update

Current Opinion in Microbiology

Volumn 14, Issue 5, 2011, Pages 564-569

  Jabes, Daniela ^a  

^a NAICONS Srl   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACHN 490; AF 1252; AFN 1252; ANTIBIOTIC AGENT; BC 3205; BC 3781; BC 7013; CB 183315; CETHROMYCIN; CG 400549; DALBAVANCIN; DELAFLOXACIN; FAB 001; GSK 1322322; JNJ Q2; LC 01 0371; LCB 01 0371; LINEZOLID; MUT 056399; NAI 107; NEMONOXACIN; NVB 302; OMADACYCLINE; ORITAVANCIN; RADEZOLID; RAMOPLANIN; RESTANZA; SOLITHROMYCIN; TARGANTA; TEDIZOLID; TELAVANCIN; TP 434; UNCLASSIFIED DRUG;

ABDOMINAL INFECTION; ACUTE PYELONEPHRITIS; ANTHRAX; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERIAL SKIN DISEASE; BACTERIUM ISOLATE; CELL MEMBRANE; CELL WALL; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PENUMONIA; COMMUNITY ACQUIRED PNEUMONIA; DIABETIC FOOT; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; REVIEW; RIBOSOME; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIA; DRUG DISCOVERY; HUMANS; RESEARCH;

EID: 80053937055     PISSN: 13695274     EISSN: 18790364     Source Type: Journal    
DOI: 10.1016/j.mib.2011.08.002     Document Type: Review

References (42)

1. Huang H., Weintraub A., Fang H., Nord C.E. Antimicrobial resistance in Clostridium difficile. Int J Antimicrob Agents 2009, 34:516-522.
2. Arias C.A., Murray B.E. Antibiotic-resistant bugs in the 21st century-a clinical super-challenge. N Engl J Med 2009, 360:439-443.
3. Kumarasamy K.K., Toleman M.A., Walsh T.M., Bagaria J., Butt F., Balakrishnan R., Chaudhary U., Doumith M., Giske C.G., Irfan S., et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010, 10:597-602.
4. Shlaes D.M. Antibiotics: The Perfect Storm 2010, Springer, The Netherlands.
5. Spellberg B., Guidos R., Gilbert D., Bradley J., Boucher H.W., Scheld W.M., Bartlett J.G., Edwards J. The epidemic of antibiotic resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:155-164.
6. Koomanachai P., Crandon J.L., Nicolau D.P. Newer developments in the treatments of Gram-positive infections. Expert Opin Pharmacother 2009, 10:2829-2843.
7. Nathwani D. A European survey of antibiotic management of methicillin-resistant Staphylococcus aureus infection: current clinical opinion and practice. Int J Antimicrob Agent 2009, 34(S1):S24-S29.
8. Yang L.P., Keam S.J. Retapamulin: a review of its use in the management of impetigo and other uncomplicated superficial skin infections. Drugs 2008, 68:855-878.
9. Johnson A.P. New Antibiotics for selective treatment of gastrointestinal infection caused by Clostridium difficile. Expert Opin Ther Pat 2010, 20:1389-1399.
10. Moellering R.C. Discovering new antimicrobial agents. Int J Antimicrob Agents 2011, 37:2-9.
11. Fishbach M.A., Walsh C.T. Antibiotics for emerging pathogens. Science 2009, 325:1089-1093.
12. Guskey M.T., Tsuji B.T. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin and telavancin. Pharmacotherapy 2010, 30:80-94.
13. St-Denis B., Mong S.M., Higgings M.E., Parr T.R., Lehoux D. Evaluation of different formulations of oritavancin in the hamster model of Clostridium difficile infection. Abstract B-703, 50th International Conference on Antimicrobial Agents and Chemotherapy 2010.
14. Chu D., Ye T., Wang B., Zurenko G., Post L., Shen J. Synthesis and biological properties of a series of novel potent glycopeptide carbamate antibacterial agents. Abstract F1-1613, 50th International Conference on Antimicrobial Agents and Chemotherapy 2010.
15. Lemaire S., Van Bambeke F., Tulkens P.M. Activity of finafloxacin, a novel fluoroquinolone with increased activity at acid pH, towards extracellular and intracellular Staphylococcus aureus, Listeria monocytogenes and Legionella pneumophila. Int J Antimicrob Agents 2011, 38:52-59.
16. Morrow B.J., He W., Amsler K.A., Foleno B.D., Macielag M.J., Lynch A.S., Bush K. In Vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone. Antimicrobial Agents Chemother 2010, 54:1955-1964.
17. Lin L., Chang L.W., Tsai C.Y., Hsu C.H., Chung D.T., Aronstein W.S., Ajayi F., Kuzmak B., Lyon R.A. Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. Antimicrob Agents Chemother 2010, 54:405-410.
18. Kim H.Y., Wiles J.A., Wang Q., Pais G.C., Lucien E., Hashimoto A., Nelson D.M., Thanassi J.A., Podos S.D., Deshpande M., et al. Exploration of the activity of 7-pyrrolidino-8-methoxyisothiazoloquinolones against methicillin-resistant Staphylococcus aureus (MRSA). J Med Chem 2011, 54:3268-3282.
19. Leach K.L., Brickner S.J., Noe M.C., Miller P.F. Linezolid, the first oxazolidinone antibacterial agent. Ann N Y Acad Sci 2011, 1222:49-54.
20. Brown S.D., Traczewski M.M. Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretative criteria, and quality control ranges. Antimicrob Agents Chemother 2010, 54:2063-2069.
21. Im W.B., Choi S.H., Park J.Y., Choi S.H., Finn J., Yoon S.H. Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent. Eur J Med Chem 2011, 46:1027-1039.
22. Prokocimer P., Bien P., Surber J., Mehra P., DeAnda C., Bulitta J.B., Corey G.R. Phase 2 randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections (cSSSI). Antimicrob Agents Chemother 2011, 55:583-592.
23. Jeong J.W., Jung S.J., Lee H.H., Kim Y.Z., Park T.K., Cho Y.L., Chae S.E., Baek S.Y., Woo S.H., Lee H.S., et al. In vitro and in vivo activities of LCB01-0371, a new oxazolidinone. Antimicrob Agents Chemother 2010, 54:5359-5362.
24. Deal watch: Novartis acquires marketing rights for novel broad-spectrum antibiotic. Nat Rev Drug Discov 2009, 8:922.
25. Hunt D., Xiao X., Clark R., O'Brien W., Fyfe C., Grossman T., Sutcliffe J., Plamondon L. TP-434 is a novel broad-spectrum fluorocycline. Poster F1-2157 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2010.
26. Grossman T., O'Brien W., Fyfe C., Sun C., Zhang W., Sutcliffe J. In vitro activity of TP-2758 against Panels of recent bacterial clinical isolates. Proceedings of the 21st European Congress of Clinical Microbiology and Infectious Diseases. 27th International Congress of Chemotherapy 2011.
27. Sun C., Hunt D.K., Clark R.B., Lofland D., O'Brien W.J., Plamondon L., Xiao X.Y. Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs. J Med Chem 2011, 54:3704-3731.
28. Novak R., Shlaes D.M. The pleuromutilin antibiotics: a new class for human use. Curr Opin Investig Drugs 2010, 11:182-191.
29. Still J.G., Schranz J., Degenhardt T.P., Scott D., Fernandes P., Gutierrez M.J., Clark K. Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects. Antimicrob Agents Chemother 2011, 55:1997-2003.
30. Woolsey L.N., Castaneira M., Jones R.N. CEM-101 activity against Gram-positive organisms. Antimicrob Agents Chemother 2010, 54:2182-2187.
31. Farrell D.J., Sader H.S., Castanheira M., Biedenbach D.J., Rhomberg P.R., Jones R.N. Antimicrobial characterization of CEM-101 activity against respiratory tract pathogens including multidrug-resistant pneumococcal serogroup 19A isolates. Int J Antimicrob Agents 2010, 35:537-543.
32. Reyes N., Aggen J., Kostrub C. In vivo efficacy of the neoglycoside ACHN-490 against Enterobacteriaceae and MRSA. abstr. F1-845. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy 2009.
33. Aggen J.B., Armstrong E.S., Goldblum A.A., Dozzo P., Linsell M.S., Gliedt M.J., Hildebrandt D.J., Feeney L.A., Kubo A., Matias R.D. Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob Agents Chemother 2010, 54:4636-4642.
34. Armstrong E.S., Miller G.H. Combating evolution with intelligent design: the neoglycoside ACH-490. Curr Opin Microbiol 2010, 13:565-573.
35. Boakes S., Cortés J., Appleyard A.N., Rudd B.A.M., Dawson M.J. Organization of the genes encoding the biosynthesis of actagardine and engineering of a variant generation system. Molec Microbiol 2009, 72:1126-1136.
36. Jabés D., Brunati C., Candiani G., Riva S., Romanó G., Donadio S. Efficacy of the new lantibiotic NAI-107 in experimental infections induced by multidrug-resistant Gram-positive pathogens. Antimicrob Agents Chemother 2011, 55:1671-1676.
37. Snydman D.R., Jacobus N.V., McDermott L.A. Activity of a novel cyclic lipopeptide, CB-183,315 against Gram-positive aerobic and anaerobic enteric isolates, including vancomycin-resistant enterococci and C. difficile strains with elevated MICs to metronidazole, vancomycin and fluoroquinolones. 21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 27th International Congress of Chemotherapy (ICC) 2011.
38. Lewandowsky T., Demarsh P., Peters P., Kulkarni S. Potent activity of GSK1322322, a novel peptide deformilase inhibitor after oral dosing in a murine multi-drug resistant Staphylococcus aureus infection. Abstract F1-2113. 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2010.
39. Singley C., Hoover J., DeMarsh P., Elefante P., Zalacain M. Efficacy of PDF inhibitor GSK1322322 against abscess infections caused by MRSA using a computer-controlled infusion system to recreate human PK profiles in rats. Poster F1-2114 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2010.
40. Infectious Diseases Society of America The 10×20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010, 50:1081-1083.
41. European Centre for Disease Prevention and Control/European Medicines Agency. European Centre for Disease Prevention and Control/European Medicines Agency Joint Technical Report. The Bacterial Challenge: Time to React.
42. Payne D.J., Gwynn M.N., Holmes D.J., Pompliano D.L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007, 6:29-40.